Despite significant progress in stroke prevention and its acute treatment, stroke remains the third leading cause of death and a leading cause of adult morbidity worldwide. By defining """"""""stroke symptom onset"""""""" in the most conservative manner, namely the time the patient was last seen well, many patients whose onset is unwitnessed are automatically ineligible for thrombolytic therapy even if their true time of onset would allow them to qualify. If a technique existed that could replace the human witness and testify that the stroke was in fact within the first few hours of true stroke onset, then these patients could be considered for alteplase treatment under current American Heart Association (AHA) guidelines, and be treated if eligible according to the inclusion and exclusion criteria. Many stroke patients are rapidly brought to the hospital within 3 hours of the time of symptom discovery, but FDA indications exclude them from consideration for intravenous alteplase if it has been greater than 3 hours since the time they were last known to be well. We propose to use advanced MR imaging as the """"""""witness"""""""" to testify as to stroke duration in those patients who do not have a human witness in a multi-center, open-label, single-arm Phase 2a safety trial of thrombolysis in these patients. We have modeled the other eligibility criteria after the ECASS 3 trial design and the current AHA guidelines in order to limit the variable of interest to the use of MR as the determinant of time of stroke onset. We will exclude patients from the study who arrive within 3 hours from last seen well since these patients are eligible for on-label treatment with thrombolysis. Because the study is open-label and investigators are unblinded, we will use the more conservative ECASS 2 definition of symptomatic intracranial hemorrhage (ICH). This is defined as any hemorrhage with neurologic deterioration, as indicated by an NIHSS score that was higher by 4 points or more than the value at baseline or the lowest value in the first 7 days, or any hemorrhage leading to death, and does not require that the ICH be classified as causally linked to the neurologic deterioration. If our study is successful, we can potentially expand use of lytics to a stroke patient population for whom little acute intervention is currently offered.

Public Health Relevance

Stroke is a leading cause of death and morbidity in the US. Thrombolysis is approved by the FDA for treatment within 180 minutes from when a patient was last seen well. Approximately 25% of stroke patients have unwitnessed onset times. This study seeks to expand IV thrombolysis to these patients using neuroimaging as the """"""""witness"""""""" to establish the stroke duration when a human witness is unavailable.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
3P50NS051343-07S1
Application #
8147555
Study Section
Special Emphasis Panel (ZNS1-SRB-R (50))
Program Officer
Janis, Scott
Project Start
2005-04-01
Project End
2014-06-30
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
7
Fiscal Year
2011
Total Cost
$1,615,536
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Atem, Folefac D; Qian, Jing; Maye, Jacqueline E et al. (2017) Linear Regression with a Randomly Censored Covariate: Application to an Alzheimer's Study. J R Stat Soc Ser C Appl Stat 66:313-328
Marini, Sandro; Morotti, Andrea; Ayres, Alison M et al. (2017) Sex differences in intracerebral hemorrhage expansion and mortality. J Neurol Sci 379:112-116
Etherton, Mark R; Wu, Ona; Cougo, Pedro et al. (2017) Structural Integrity of Normal Appearing White Matter and Sex-Specific Outcomes After Acute Ischemic Stroke. Stroke 48:3387-3389
(2017) 19th Workshop of the International Stroke Genetics Consortium, April 28-29, 2016, Boston, Massachusetts, USA: 2016.001 MRI-defined cerebrovascular genomics-The CHARGE consortium. Neurol Genet 3:S2-S11
Lima, Fabricio O; Silva, Gisele S; Furie, Karen L et al. (2016) Field Assessment Stroke Triage for Emergency Destination: A Simple and Accurate Prehospital Scale to Detect Large Vessel Occlusion Strokes. Stroke 47:1997-2002
Atem, Folefac D; Qian, Jing; Maye, Jacqueline E et al. (2016) Multiple Imputation of a Randomly Censored Covariate Improves Logistic Regression Analysis. J Appl Stat 43:2886-2896
Anderson, Christopher D; Falcone, Guido J; Phuah, Chia-Ling et al. (2016) Genetic variants in CETP increase risk of intracerebral hemorrhage. Ann Neurol 80:730-740
Gesierich, Benno; Opherk, Christian; Rosand, Jonathan et al. (2016) APOE ?2 is associated with white matter hyperintensity volume in CADASIL. J Cereb Blood Flow Metab 36:199-203
Reijmer, Yael D; van Veluw, Susanne J; Greenberg, Steven M (2016) Ischemic brain injury in cerebral amyloid angiopathy. J Cereb Blood Flow Metab 36:40-54
Hirai, Kelsi K; Groisser, Benjamin N; Copen, William A et al. (2016) Comparing prognostic strength of acute corticospinal tract injury measured by a new diffusion tensor imaging based template approach versus common approaches. J Neurosci Methods 257:204-13

Showing the most recent 10 out of 123 publications